- Home
- Equipment
- australasia
- prostate tumors
Show results for
Refine by
Prostate Tumors Equipment Supplied In Australasia
7 equipment items found
Manufactured by:Radiopharm Theranostics based inCarlton, AUSTRALIA
Pivalate is the invention of Professor Eric Aboagye of Imperial College London: Pivalate is an 18F-FPIA radiotracer, based on a short chain carbohydrate which utilises the early steps of fatty acid oxidation and is very stable; In comparison to the clinical standard in PET imaging, 18F-FDG in prostate and brain cancers, Pivalate showed superior imaging performance and was equally good for two ...
Manufactured by:Radiopharm Theranostics based inCarlton, AUSTRALIA
PSA-mAb is the invention of Professor David Ulmert formerly of Memorial Sloan Kettering and now ...
by:Starpharma Holdings Limited based inMelbourne, AUSTRALIA
DEP® docetaxel is an enhanced version of docetaxel (Taxotere®) – widely used for breast, lung & prostate cancer. Docetaxel (Taxotere®) is a commonly used chemotherapy agent despite having multiple US FDA “Black Box” warnings. DEP® docetaxel is a detergent free, aqueous formulation of docetaxel. ...
by:Starpharma Holdings Limited based inMelbourne, AUSTRALIA
DEP® radiotheranostic conjugates have the potential to minimise off-target toxicity, optimise pharmacokinetics and enhance efficacy when used alone or in combination with other therapeutic approaches. The versatility of Starpharma’s DEP® platform means it can be used with a wide range of therapies and types of molecules (e.g., small molecule drugs, peptides, antibodies, ...
by:Chimeric Therapeutics based inCarlton South, AUSTRALIA
CHM 1101 (CLTX CAR T) is an optimized first-in-class CAR T cell therapy that uniquely utilizes Chlorotoxin (CLTX), a 36-amino acid peptide derived from deathstalker scorpion venom as its tumour targeting ...
Manufactured by:Avania based inBrunswick, AUSTRALIA
Look to Avania’s urology team for the precise expertise you need to conduct and advance your research. From feasibility studies and protocol design through post-approval, our team guides you while sharing our specialized urology ...
by:Starpharma Holdings Limited based inMelbourne, AUSTRALIA
DEP® cabazitaxel is an enhanced version of leading prostate cancer drug cabazitaxel (Jevtana®). Cabazitaxel (Jevtana®) had global sales of €536M in 2020 despite having multiple US FDA “Black Box” warnings. ...